Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Brain Neoplasms × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 7 Precancerous Conditions 3 Adenomatous Polyposis Coli 3 Prostatic Neoplasms 2 Glioma 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Osteosarcoma Recurrent 1 Osteosarcoma 1 Neoplasms 1 Melanoma 1 Medulloblastoma 1 Lung Neoplasms 1 Keratosis, Actinic 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Polyps 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Adenomatous Polyps 1

Interventions

Temozolomide 133 Radiosurgery 101 Radiotherapy 83 Bevacizumab 83 Magnetic Resonance Spectroscopy 56 Carboplatin 44 Etoposide 31 pembrolizumab 30 Irinotecan 28 Cyclophosphamide 28 Surgical Procedures, Operative 27 Nivolumab 27 Erlotinib Hydrochloride 26 Radiation 24 Carmustine 24 Lomustine 21 Filgrastim 21 Cisplatin 20 Trastuzumab 19 Ipilimumab 19 Aminolevulinic Acid 18 Vincristine 17 Capecitabine 17 Specimen Handling 16 Pemetrexed 16 Mental Status and Dementia Tests 16 Topotecan 15 Lapatinib 13 Imatinib Mesylate 13 Granulocyte Colony-Stimulating Factor 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡